CHINESE VACCINE generated disappointment with 50% efficacy / Argentina News

While trials with a Chinese vaccine showed low efficacy, negotiations began in Brazil to purchase the AstraZeneca vaccine

Many companies and state entities in some countries have begun to develop vaccinations against him coronavirus. Since the beginning of the pandemic, studies began on this virus, and the search for the vaccine was promptly triggered.

In addition, each country has made agreements with different companies to provide themselves with the necessary vaccines to immunize their population.

Brazil, for example, made various agreements, including clinical trials for the Chinese vaccine, CoronaVac. However, after clinical trials showed only 50% efficacy, the neighboring country’s government accelerated negotiations with India to seek 2 million doses of the vaccine developed by AstraZeneca-Oxford.

The government of President Jair Bolsonaro decided on Friday to make a last-minute agreement with that of the Prime Minister of India, Narendra Modi. The objective is to send a Brazilian plane to search for 2 million vaccines from AstraZeneca-Oxford, which is manufactured by an Indian laboratory in Mumbai, according to what government sources have reported.

The Chinese vaccine has shown an efficacy just over 50%

As mentioned, the negotiations came three days after disappointing results were seen in the country in clinical trials with the Chinese vaccine CoronaVac, which showed a effectiveness barely older than fifty%.

The Chinese vaccine and its results

Those responsible for Butantan Institute of São Paulo revealed the results of these studies last Tuesday. The information was somewhat disappointing, given that the efficacy of the laboratory-produced vaccine Sinovac it was low. These data were confirmed in a press conference given by the institute’s medical director of clinical research, Ricardo Palacios.

It is important to note that the minimum percentage efficacy of a vaccine recommended by the World Health Organization (WHO) and by the National Health Surveillance Agency (Anvisa) is 50 percent. This means that, even with these results, the CoronaVac could still be approved for application by a minimal margin.

The main problem was that last week the Butantan Institute had stated that, according to the results obtained so far, the Chinese vaccine had shown an efficacy of 78% in mild cases and 100% in moderate cases. That is why this week the new results fell surprisingly and they disappointed to many people. In addition, they cast doubt on the true efficiency that this product might have.

São Paulo bought 6 million doses of the Chinese vaccine, although it has not yet received approval in Brazil

São Paulo bought 6 million doses of the Chinese vaccine, although it has not yet received approval in Brazil

Beyond all these considerations and details about the Chinese vaccine, it is worth mentioning that Saint Paul has already bought 6 million doses CoronaVac, which are currently kept in a hangar at Guarulhos airport.

“The vaccine is extremely safe, no one will become anything other than a protected human being,” Palacios said at the press conference. As has emerged, this was a ironic reference to the words of Bolsonaro, who had shown distrust about immunizations and had said that people who were vaccinated could become alligators.

Finally, it should be mentioned that the Butantan experts assured that they still could not determine how long the immunity of the individuals vaccinated and may need to be revaccinated to ensure that protection.